Muse therapy: Preliminary clinical observations

Urology

Volumn 50, Issue 5, 1997, Pages 809-811

  Werthman, Philip ^a   Rajfer, Jacob ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAPAVERINE; PHENTOLAMINE MESYLATE; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; IMPOTENCE; INTRACAVERNOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PAIN; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; SYNCOPE; TRANSURETHRAL DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ALPROSTADIL; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; URETHRA; VASODILATOR AGENTS;

EID: 0030657031     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00448-2     Document Type: Article

References (13)

1. NIH Consensus Developement Panel on Impotence: NIH Consensus Conference: impotence. JAMA 270: 83-90, 1993.
2. Brindley GS: Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 143: 332-337, 1983.
3. Irwin MK, and Kata EJ: High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 43: 84-87, 1994.
4. Weiss JN, Badlani GH, Ravelli R, and Brettschneider N: Reason for high drop out rate with self injection therapy for impotence. Int J Impotence Res 6: 171-174, 1994.
5. Gupta R, Kirschen J, Barrow II RC, and Eid JF: Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 157: 1681-1686, 1997.
6. Wolfson B, Pickett S, Scott NE, DeKernion JB, and Rajfer J: Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 42: 73-75, 1993.
7. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, et al: Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 336: 1-7, 1997.
8. Hellstrom WJ, Bennett AH, Gesundheit N, Kaiser FE, Lue TF, Padma-Nathan H, Peterson CA, Tam PY, Todd LK, Varady JC, et al: A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 48: 851-856, 1997.
9. Ishii N, Watanabe H, Irisawa C, et al: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J Urol 141: 323-325, 1989.
10. Bechara A, Casabe A, Cheliz G, Romano S, Rey Y, and Fredotovich N: Prostaglandin E1 versus mixture of prostaglandin E1, papavarine and phentolamine in nonresponders to high papavarine plus phentolamine doses. J Urol 155: 913-914, 1996.
11. Waldhauser M, and Schramek P: Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J Urol 140: 525-527, 1988.
12. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, and Resnick MI: Side effects of self administration of intracavernous papavarine and phentolamine for the treatment of impotence. J Urol 141: 54-57, 1989.
13. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impotence Res 8: 47-52, 1996.